Candel therapeutics reports second quarter 2022 financial results and recent corporate highlights

Needham, mass., aug. 05, 2022 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended june 30, 2022 and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking